Matthew J. Hadfield

Also affiliated with Rhode Island Hospital

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 4 papers. Top paper: “Advances in Liquid Biopsy Technology and Implications for Pancreatic Cancer”.

Advances in Liquid Biopsy Technology and Implications for Pancreatic Cancer

International Journal of Molecular Sciences(2023)10.3390/ijms24044238

N/A

0DataRank · unranked

42 citations

Michael May, Matthew J. Hadfield, Attila A. Seyhan, Wafik S. El‐Deiry, Alexander G. Raufi

Who goes first? Patterns of cancer drug approvals across four major regulatory authorities: EMA, FDA, Health Canada, and PMDA.

JCO Oncology Practice(2023)10.1200/op.2023.19.11_suppl.149

N/A

0DataRank · unranked

2 citations

Sanjay Mishra, Matthew J. Hadfield, Bishal Gyawali, Andrew J. Cowan, Ali Raza Khaki +3 more

Multi-organ immune-related adverse events from immune checkpoint inhibitors and their downstream implications: a retrospective multicohort study

The Lancet Oncology(2024)10.1016/s1470-2045(24)00278-x

N/A

0DataRank · unranked

95 citations

Wenxin Chen, Sara Khattab, Katie Roster, Nga Nguyen, Boshen Yan +14 more

The evolving posology and administration of immune checkpoint inhibitors: subcutaneous formulations

Trends in cancer(2024)10.1016/j.trecan.2024.03.006

N/A

0DataRank · unranked

11 citations

David J. Benjamin, Jonathan Krell, Jeremy L. Warner, Mark P. Lythgoe, Matthew J. Hadfield